Objective To investigate the distribution of rats’ pelvic muscles motoneurons innervated by artifical somatic-autonomic reflex arc. Methods Thirty-five SD rats were randomly divided into normal group (n=10) and model group (n=25). The rats in the normal group were given no treatment. In the normal group, the artifical somatic-autonomic reflex arc was established. Six months after establishing the model, external urethral sphincter (EUS), ischiocavernosus (IC), bulbocavernosus (BS) and external anal sphincter (EAS) of the rats in normal group(n=10) and of the rats in model group A (n=20) were injected with fluorogold (FG). The reversal neural tracing was done. FG positive neural cells were observedby fluorescent microscope. Malt agglutinator binding horseradish peroxidase (WGA-HRP) was injected into L4 spinal cord of the rats in model group B (n=5) as the anterograde tracer. After being treated with TMB-HRP reaction, the axon endings in the neuromuscular junction in pelvic striated muscles (EUS, IC, BS, EAS) were investigated with light microscopes. Results In normal group, EUS and IC injections resulted in transport of FG to neurons in the dorsolateral nucleus (DL) of the ventral horn of the L5～S1, and BS and EAS in the dorsomedial nucleus (DM) of ventral horn in the L5～S1. In the model group A, EUS, IC, BS andEAS injections resulted in transport of FG to neurons in the left ventral horn in the L4. In model group B, after WGA-HRP was injected into the L4 left ventral horn, HRP positive axon terminals were observed in the EUS, IC, BS and EAS. Conclusion In the normal rats, the pelvic striated muscles motoneurons locate in the ventral horn of L5～S1. In the model rats, the pelvic striated muscles motoneurons innervated by artificial somatic-autonomic reflex arc locate in the ventral horn of the L4. After the artificial somaticautonomic reflex arc is established, the isomerous nerve fiber innervates EUS, IC, BS and EAS.
Objective To demonstrate the efficacy, tolerability, and safety of domestic Acarbose tablet compared with Glucobay (Acarbose tablet produced by Bayer company) in patients with type 2 diabetic patients. Method A multicenter randomized controlled parallel-group comparison study was conducted. 177 Chinese type 2 diabetic patients were recruited from 4 clinical centers. The patients were divided randomly into domestic Acarbose tablet (A group) or Glucoby (B group) treatment group. The trial consisted of a 2-4 weeks equilibrated period followed by an 8 week course of treatment. Results 165 patients have finished the trial (81 in A group and 84 in B group). After 4 weeks of treatment, the mean of fasting blood glucose (FBG) in A and B group were reduced 1.61 and 2.08 mmol/L respectively, and mean of postprandial blood glucose (PBG) lowered 5.06 and 5.09mmol/L respectively. After 8 weeks of treatment, the mean of FBG were reduced 1.95 and 2.62mmol/L respectively, and mean of PBG lowered 4.88 and 5.98 mmol/L, respectively, and mean of HbA1c were lowered 1.13% and 1.20% respectively in A and B group. The differences in reduction of FBG, PBG, and HbA1c between A and B group were no statistic significance. The serum triglyceride levels and BMI were decreased significantly in both A, B groups. 3 patients who drinking wine during trial on A group had asymptomatic elevations in serum transaminases that normalized in 2 weeks after stopped drinking and Acarbose withdrawal. Flatulence was the most common side effect. Conclusions In this multicenter study, domestic Acarbose tablet 50 mg t.i.d. was an effective, safe, and generally well-tolerated therapy as similar as Glucobay in type 2 diabetic patients.